MIRA Pharmaceuticals, Inc. - 10-Q Summary (Q1 2025)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing two neuroscience programs: Ketamir-2 (an oral ketamine analog for pain, depression, and PTSD) and MIRA-55 (an oral pharmaceutical marijuana molecule for anxiety and cognitive decline). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,783,779) | $(1,717,771) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.15) |
| Cash and Cash Equivalents (End of Period) | $1,206,285 | $3,528,695 |
| Stockholders' Equity | $1,294,165 | $3,156,785 |
| Total Liabilities | $106,173 | $723,349 |
| Operating Cash Flow | $(1,630,027) | $(1,049,536) |
Expense Breakdown (Q1 2025): General and Administrative expenses were $1.49 million, and Research and Development expenses were $0.31 million.
Material Changes vs. Prior Period
- Liquidity Decline: Cash reserves decreased by approximately $1.63 million, dropping from $2.83 million at year-end 2024 to $1.21 million at March 31, 2025.
- Liability Reduction: Total current liabilities decreased significantly from $723,349 to $106,173, primarily due to the reduction of accrued liabilities from $300,000 to $5,500.
- Expense Shifts: R&D expenses decreased by approximately $448,000 compared to Q1 2024, attributed to the timing of Phase 1 trial initiation. Conversely, G&A expenses increased by approximately $485,000, driven largely by higher stock-based compensation ($874,812 in Q1 2025 vs. $500,210 in Q1 2024).
- Equity Dilution: The company issued 252,802 shares of common stock during the quarter (250,000 vested RSUs and 2,802 shares via ATM offering).
Outlook, Risks, and Unusual Items
- Going Concern Warning: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months. Management expects to fund operations only through Q3 2025 with current cash and anticipates needing additional financing.
- Nasdaq Compliance Risk: The company received notice of non-compliance with Nasdaq Listing Rule 5550(b)(1) due to stockholders' equity falling below the $2.5 million minimum. A plan to regain compliance by October 6, 2025, was accepted, contingent on closing the SKNY merger and utilizing the ATM facility.
- Strategic Acquisition: On March 19, 2025, MIRA entered a binding LOI to acquire SKNY Pharmaceuticals, Inc. via a stock exchange. The transaction includes a $5 million capital infusion from SKNY and adds SKNY-1 (a weight loss and smoking cessation candidate) to the pipeline. The merger was approved by the Board on May 8, 2025, pending shareholder approval.
- Operational Milestones: Phase 1 clinical trials for Ketamir-2 began in Q1 2025. Positive neurotoxicity study results were announced in May 2025.
Investor Verification Checklist
- Capital Runway: Verify the timeline for securing additional funding, as current cash ($1.2M) may not sustain operations beyond Q3 2025.
- SKNY Merger Status: Monitor the progress of the SKNY Pharmaceuticals acquisition and the associated $5M capital infusion, which is critical for Nasdaq compliance.
- Nasdaq Delisting Risk: Confirm the company's ability to meet the October 6, 2025, deadline to restore stockholders' equity to $2.5M to avoid delisting.
- Related Party Transactions: Review the license agreement with MIRALOGX (a related party) and the terms of the SKNY acquisition, noting SKNY's license is also from MIRALOGX.
- ATM Facility Usage: Track the utilization of the At-The-Market (ATM) offering facility, which was recently amended to a $7 million cap.